Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 30, 2023

CHMP recommends approval of Bristol Myers Squibb’s Reblozyl

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol Myers Squibb’s Reblozyl (luspatercept) for adult patients with anemia associated with non‑transfusion-dependent (NTD) beta thalassemia.

Continue
A giemsa stained blood smear from a person with beta thalassemia. Credit: Dr Graham Beards / commons.wikimedia.org.
January 25, 2023

AFT and Salus Pharmaceuticals sign agreement for pain treatment Maxigesic IV

The agreement with Salus for the therapy covers Lithuania, Estonia, Latvia, Croatia, Slovenia, Serbia, North Macedonia, Montenegro, and Bosnia. Credit: National Cancer Institute on Unsplash.
January 24, 2023

TScan Therapeutics receives FDA clearance for IND applications

T-Plex will enable customised combinations of TCR-Ts to be administered to patients based on the targets and HLAs expressed in their tumours. Credit: National Cancer Institute on Unsplash.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals January 26, 2023

Rewind Therapeutics raises funding to further lead programme into clinical development

Pharmaceutical Business Review

ReCode Therapeutics to receive strategic investment from Cystic Fibrosis Foundation

Vistagen agrees to acquire Pherin Pharmaceuticals

Kite signs agreement to acquire biotech company Tmunity Therapeutics

Popular

  1. EMA accepts Eisai, Biogen’s lecanemab MAA for review to treat AD
  2. Genexine receives FTD for DNA vaccine to treat advanced cervical cancer
  3. US FDA grants fast track designation to Evaxion Biotech’s personalised cancer therapy
  4. Exegenesis Bio receives US FDA clearance for EXG102-031 IND application
  5. Forge Biologics receives EMA PRIME designation for Krabbe disease drug

PRESS RELEASES

Sofgen Pharmaceuticals Launches New Site
Sofgen Pharmaceuticals Launches New Site
CDP Score: Gerresheimer Upgraded to ‘A-‘ for Performance on Climate Change
CDP Score: Gerresheimer Upgraded to ‘A-‘ for Performance on Climate Change
Pharmaceutical Business Review
Innovating for a Better Life – Gerresheimer with Sustainable Solutions for Biotech and Pharma
Sofgen Pharmaceuticals Obtains Drug Establishment License #100241-A from Health Canada
Sofgen Pharmaceuticals Obtains Drug Establishment License #100241-A from Health Canada
Gerresheimer to Expand Significantly in High Value Solutions and Further Accelerates its Sustainable Profitable Growth
Gerresheimer to Expand Significantly in High Value Solutions and Further Accelerates its Sustainable Profitable Growth

Suppliers

Whitepapers

Usability Testing ‒ What, Why & Recent Results
Usability Testing ‒ What, Why & Recent Results
A Global Top Ten Pharma Client Saw Significant Spend Reduction Through the Use of RWS Managed Services
A Global Top Ten Pharma Client Saw Significant Spend Reduction Through the Use of RWS Managed Services
Technology-Enabled Safety & Pharmacovigilance Solution
Technology-Enabled Safety & Pharmacovigilance Solution